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EpigeneticsHuntington's disease (HD) is a fatal genetic disorder characterized by triad clinical symptoms of chorea, emotion-
al distress, and cognitive decline. Genetic mutation in HD is identiﬁed by an expansion of CAG repeats coding for
glutamine (Q) in exon 1 of the huntingtin (htt) gene. The exact mechanism on howmutant htt leads to the selec-
tive loss ofmedium spiny neurons (MSNs) in the striatum is still unknown. Recent studies suggest that nucleolar
stress and dysfunction are linked to the pathogenesis of HD. Alterations of the nucleolar activity and integrity
contribute to deregulation of ribosomal DNA (rDNA) transcription in HD pathogenesis. Furthermore, epigenetic
modiﬁcations in the nucleolus are associated with neuronal damage in HD. In this review, we discuss about how
post-translational modiﬁcations of upstream binding factor (UBF) are affected by histone acetyltransferase and
histone methyltransferase and involved in the transcriptional regulation of rDNA in HD. The understanding of
epigenetic modulation of UBF-dependent rDNA transcription in the nucleolus may lead to the identiﬁcation of
novel pathological markers and new therapeutic targets to treat HD. This article is part of a Special Issue entitled:
Role of the Nucleolus in Human Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
1.1. From heritable dancing disorder (chorea) to Huntington's disease (HD)
Huntington's disease (HD) is an autosomal dominant genetic disor-
der featured by neurological symptoms with chorea (uncoordinated
movement), psychiatric symptoms, and memory loss. The frequency
of HD is reported as high as 10 cases per 100,000 and having a new
mutation rate of 1–3% [1]. The occurrence of HD is not limited to a
speciﬁc region or population but found throughout the globe in all
races and ethnic groups [2]. The shores of Lake Maracaibo in
Venezuela particularly have the highest HD frequency. The number of
HD patients in United States alone reaches 30,000 and those at genetic
risk of HD are considered to be 200,000.
Before 17th century, Huntington's disease (HD) was a mysterious
dancing disorder (chorea) that shows jerking and twitching of muscles.
Due to the lack of medical knowledge at that time, the people withgtin; mthtt, mutant htt; MSNs,
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ights reserved.involuntary movement as a feature of HD were being regarded as
witches possessed by the devil [3]. In 1872, George Huntington, an
American physician, provided the ﬁrst clinical description of HD and
its hereditary nature [4]. The initial understanding of HD as a chronic
encephalitis has been replaced by Jergelsma in 1908, who described
the characteristic neuropathological alterations affecting the basal
ganglia that are now established as the imperative pathoanatomical
feature of HD [5,6]. Gross atrophy of the neostriatal nuclei, the caudate
nucleus, and putamen, combined by detectable neuronal loss and
astrogliosis are the most salient neuropathological alterations of HD
[7–9]. Within HD, not all striatal neurons are equally inﬂuenced, and
there appears to be a selective pattern of neuronal vulnerability and
topographic susceptibility. During the earliest stage of disease medium-
sized spiny neurons are most severely affected while intrinsic locally
arborizing aspiny striatal interneurons are comparably spared [9–15].
Most importantly, the Huntington's disease Collaborative Research
Group (HCRG) presented in 1993 that a previously unidentiﬁed ‘inter-
esting transcript (IT) 15’ on human chromosome 4 was mutated in
patients with HD and genetically linked to HD [16]. HCRG's reported
HD-related lethal gene was referred to as huntingtin (htt). The expan-
sion of the wildtype htt allele that typically contains 15–35 CAG triplets
in exon 1 to 36 ormore repeats has been determined to be themutation
of htt gene. Furthermore, HD is considered to be related to other neuro-
degenerative diseases such as spinal and bulbar muscular atrophy
(SBMA, also referred to as Kennedy's disease (KD)) and spinocerebellar
ataxias (SCAs) which are also caused by similar trinucleotide CAG
repeat mutations. To be more speciﬁc, SBMA occurs when androgen
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tract within the SCA1 gene product ataxin-1 causes SCA1 [17,18]. The
signiﬁcance of CAG expansion is observed in cases where affected
individuals with greater number of CAG repeats show younger age of
onset. In addition, there is a strong inverse relationship between age
of onset and CAG repeat number in HD.
The cytoplasmic and vesicular protein, htt, is ubiquitously expressed
and heterogeneously found in neurons throughout the brain. Numerous
hypothetical pathologic mechanisms have been proposed since dis-
covering htt gene but a direct pathway from the genetic mutation
to neuronal degeneration has yet to be established. Even though the
deﬁnitive functionality of htt remains unknown, it has been postulated
that htt is involved in intracellular transport, autophagy, transcription,
mitochondrial function, and signal transduction. On the other hand,
mutant htt (mthtt) results in the inhibition of fast axonal transport
and destabilization of microtubules within the cell [19,20]. Within
heterozygous HD, both normal and mutant alleles are expressed. As a
“gain of function”, the expression of mutant htt protein is toxic and it
triggers the pathologic cascades of HD. In contrast, the deletion of the
normal htt gene is also lethal indicating that the function of normal
htt is essential in survival [21–28]. The engagement in pathologic
protein–protein interactions between mutant htt and its proteolytic
fragments is well established and accepted. This engagement leads
to alterations of cellular pathways that make neurons to be more
vulnerable to generic stresses, ultimately resulting in neuronal damage
and death [29]. Additionally, mutant htt interactomes involve trans-
criptional dysregulation, mitochondrial dysfunction, proapoptotic
signaling, oxidative injury, excitotoxicity, inﬂammatory reactions,
and malfunctioning proteolysis. Since the ﬁrst clinical description
of HD by George Huntington, there has been a strong progression
towards the understanding of the disease mechanisms. However, a
treatment to prevent the onset or to delay the insidious and unyielding
course of HD is currently unavailable [30].
1.2. Epigenetic alterations in HD
A term “epigenetics” was described by Dr. Waddington to explain
the biological events that are unexplainable by conventional genetic
principals [31]. The ﬁeld of epigenetics has evolved since its introduc-
tion, and is nowdeﬁned as the study connecting genotype to phenotype
in the absence of DNA sequence alteration [32]. In consideration to
this, epigenetics is regarded as a highly beneﬁcial ﬁeld to investigate
features and mechanisms responsible for the temporal and spatial con-
trol of gene activity regulated by processes beyond mutations in DNA
sequence [33]. Epigenetic modiﬁcations explain for and encompass an
array of molecular modiﬁcations to both chromatin and DNA, including
ncRNA regulation. For many genes in general, they contain DNA meth-
ylation sites (CpG islands) in their promoters [34]. This indicates that
marked hypo- or hyper-DNA methylation may explain for signiﬁcant
components of the molecular and pathogenic complexity of human
genomes. Expanding number of evidence suggests and point towards
the alterations of epigenetic modiﬁcations to constitute a basic
molecular mechanism contributing to HD pathogenesis. What the
understanding of epigenetic mechanisms holds for is the opportunity
to gain imperative insights leading to the identiﬁcation of novel bio-
logical markers and therapeutic interventions to treat HD [35].
A growing body of evidence indicates that nucleolar stress and
dysfunction are linked to the pathogenesis of HD. The nucleolus is a
subnuclear compartment possessing the transcription machinery of
ribosomal genes and the ribosomal DNA (rDNA) encoding ribosomal
RNA (rRNA) [36]. The rDNA is organized as tandem repeats in the
nucleolus and is transcribed into 47S precursor rRNA by a nucleolar
transcription complex, consisting of RNA polymerase I and other co-
regulatory factors [37]. Neurons have prominent nucleoli but the
role of this structure and the regulatory mechanism of rDNA trans-
cription are poorly understood [38]. RNA polymerase I and upstreambinding factor (UBF) are major molecular components for the forma-
tion of active nucleolar organizer regions and maintenance of rRNA
transcriptional activity [39]. It has beenpreviously known that nucleolar
accessory bodies (Cajal bodies) are associated with disorders caused by
expansions of CAG repeats within genes, including HD [39]. Recently,
our group and others have found that alteration of epigenetic com-
ponents and deregulation of transcriptional machinery are directly
involved in the down regulation of ribosomal RNA (rRNA) expression
and neuronal damage in HD [40,41] Together, in the present paper,
we are going to address and discuss the epigenetic changes and mech-
anism that are associated with the nucleolar-dependent pathogenesis
in HD.
2. Epigenetic modiﬁcations in the nucleolus of HD
2.1. UBF acetylation in HD
UBF is a nucleolar transcription factor of the high mobility group
(HMG) protein family and contains six HMG box DNA binding motifs.
UBF consists of two polypeptides (UBF1 and UBF2, 97 and 94 kDa,
respectively), which arise from alternative splicing of a single transcript
[42]. UBF1 and 2 form hetero- and homodimers but UBF2 is ﬁve-fold
less active than UBF1, and mechanisms by which UBF2 provides such
poor transcriptional activity are not known [43]. UBF is essential for
rDNA transcription by inducing remodeling of ribosomal gene chroma-
tin and further playing a structural role by binding to other sequences
across the entire rDNA [36]. UBF targeting to regions of heterochromatin
is sufﬁcient to induce large-scale chromatin decondensation [44]. UBF
binding throughout the rDNA gene repeat might therefore contribute
to the formation of the active chromatin state of rDNA genes [45].
Recently, we found that transcriptional modulation of rDNA is altered
in HD, and both UBF and CREB binding protein (CBP) contribute to
altered nucleolar chromatin remodeling and rRNA expression in HD.
We found that protein levels UBF1, CBP, and UBF-mediated trans-
criptional activity of rDNA are impaired in cellular and animal model
of HD as well as in HD patients [40]. Our study shows that UBF1 protein
levels in the striatum were signiﬁcantly decreased and the 45S was
down regulated in R6/2 mice in comparison with WT controls. These
data indicate that abnormal protein level of UBF1 protein levels
correlates with impaired ribosomal transcription in HD mice.
Post-translational modiﬁcations of UBF, such as acetylation and
phosphorylation, have an important role in the control of rDNA tran-
scription [46]. Transcription factor acetylation is responsible for both
activation and subnuclear localization [47]. CBP functions as a HAT in
acetylating histones that contributes to transcription by remodeling
the chromatin structure and functions as a transcriptional cofactor
[48]. A loss of CBP function interferes with transcription by altering
the acetylation level of histones and chromatin structure in neurons
and also by inhibiting recruitment of the basal transcription machinery
to the promoter [49,50]. Interestingly, the sequestration of CBP mole-
cule by mthtt protein was found in intranuclear inclusions of striatal
neurons and other neurons of HD [22,51] (Fig. 1). The polyQ repeats
in mthtt interact physically with CBP and deregulate its intrinsic HAT
activity and transcriptional coactivator function [52,53]. Accordingly,
the blocking of CBP activity by mthtt causes the hypoacetylation and
hypermethylation of histoneproteins and the subsequent transcription-
al dysfunction of neurons in HD [54–58]. These speciﬁc interactions and
epigenetic modiﬁcations are attributable to pathological transcriptional
dysfunction [59]. Importantly, we determined that CBP interacts with
UBF1, acetylates UBF1, and modulates rDNA transcription in HD. UBF
acetylation is also important for cell cycle-dependent regulation of
rRNA expression. It has been proposed that the transcription of rDNA
is regulated upon the inﬂuence of two opposite processes through UBF
acetylation by CBP and deacetylation by HDAC [26]. In this context,
CBP-dependent acetylation of UBF provides a thread of mechanism on
the transcription activation of rDNA [46]. Indeed, we found that the
Fig. 1. Mutant huntingtin (mthtt) sequestrates CBP and disrupts CBP-mediated UBF activation in the nucleolus of HD. In normal conditions, CBP maintains the acetylation status of
UBF through HAT activity and regulates the transcription of rDNA by interacting with transcriptional complexes including RNA polymerase I (Pol I). In HD, mthtt sequestrates CBP in nu-
clear inclusions (aggregate formation) and deregulates UBF-dependent nucleolar transcription. Consequently, imbalanced rDNA transcription leads to neuronal damage in HD.
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of CBP function in both HD cells and HDmice. Our data shows that UBF1
and CBP interact in intact neurons. Reduced levels of acetylated UBF1
correlate with the reduced CBP level and activity in HD. We further
demonstrated that the HAT activity of CBP directly controls UBF1 acety-
lation and this was found using a HAT domain deletion mutant of CBP
that caused a marked reduction of UBF1 acetylation. Our ﬁndings
indicate that the neurodegenerative process in HD is associated with
changes in adaptive rDNA transcription caused by altered CBP acetyl-
transferase that affects the balance of acetylated and deacetylated
UBF1 [40,22] (Fig. 1).
The LC-MALDI-MS/MS analysis identiﬁed the speciﬁc acetylation site
of UBF1 from in vitro-acetylated UBF protein by CBP [40]. CBP acetylates
UBF1 at K352 that resides in the HMG3 domain. Mutations at K352 to
alanine (A), glutamine (Q), and arginine (R) abrogate the acetylation
of UBF1, as well as the transcriptional activation of UBF1 in response
to CBP. This data conﬁrms that the acetylation of UBF1 by CBP has a
pivotal role in rDNA gene transcription. Consequently, due to the lack
of CBP-dependent acetylation of UBF1, UBF1-induced rDNA expression
is disrupted in HD models [46,60]. It is unclear, however, whether
mtHtt and HD-related cellular changes modulate the association of
HDAC to the UBF1 complex. Future study remains to deﬁne precisely
how UBF1 protein is deacetylated and what other factors are involved
in this process. This will provide a better understanding of the rDNA
transcription and ribosomal synthesis in the pathogenesis of HD.Fig. 2. A scheme represents an epigenetic mechanism that abnormal activity of his-
tone H3K9-speciﬁc methyltransferase (ESET/SETDB1) leads to UBF trimethylation
and impaired rDNA transcription in HD. ESET methylates UBF and UBFme3-dependent
nucleolar chromatin condensation results in the repression of rDNA transcription, and
subsequent reduction of 18S and28SRNA.Down regulation of rDNA transcription contrib-
utes to striatal dysfunction and neurodegeneration in HD.2.2. UBF methylation in HD
The motor symptoms of HD are largely a consequence of profound
neuronal damage in theGABAergicMSNs [3]. Deregulation of chromatin
remodeling is regarded as one of the mechanisms by which mutant
mthtt contributes to cell death of MSNs in the striatum [3]. Mthtt not
only blocks the intrinsic HAT activity of CBP but also induces epigenetic
enzymes such as histonemethyltransferases (HMTs) [52,61]. These spe-
ciﬁc epigenetic alterations show how mthtt modulates transcriptional
signaling cascades that initiate a number of downstream pathophysio-
logical mechanisms relevant to HD. ERG-associated protein with SET
domain (ESET/SETDB1) is a histone H3K9-speciﬁc methyltransferase
that contains both tudor and methyl-CpG binding domains that
converge transcription and RNA processing factors [62]. It also acts asa signature motif for proteins regulating methylated DNA silencing
[62]. SETDB1 is involved in neuronal dysfunction through its histone
methyltransferase activity and the epigenetic silencing of neuronal
genes [56]. However, the roles of SETDB1 on nucleolar chromatin land-
scaping and rDNA transcription have not been fully investigated yet
[63]. We have recently found that elevations of SETDB1 expression and
H3K9me3 level are correlated with transcriptional deregulation and
neurodegeneration in HD [56,64]. To examine the links between
SETDB1 activity and nucleolar function, we evaluated whether SETDB1
interacts with UBF and contributes to the chromatin organization of
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increased levels of methylated UBF are correlated with the increased
SETDB1 activity, a pathological event found inHD (Fig. 2). Aswe expect-
ed, the levels of SETDB1 protein and methylated UBF were signiﬁcantly
increased in the striatum of R6/2 transgenic HD mice and human
HD patients (unpublished data). Second, we determined that SETDB1
physically interacts with UBF and methylates it in intact neurons.
The methyltransferase activity of SETDB1 is directly responsible for
UBF methylation. Accordingly, SET domain deletion mutants of SETDB1
resulted in amarked reduction of UBFmethylation. In general, K (lysine)
residues are mono-, di, or trimethylated, and the status of methylation
contributes to different functional outcomes [65]. We conﬁrmed that
UBF is presented as a trimethylated form in intact cells. In addition,
UBF is trimethylated by SETDB1 in vitro. We performed LC-MALDI-
MS/MS analysis in vitro on UBF-HMG protein methylated by SETDB1
and identiﬁed the speciﬁc methylation site of UBF. We found that
SETDB1methylates UBF at the K232/254 residues of the HMG2 domain
(unpublished data). Accordingly, mutations at K232/254 blocked UBF
trimethylation and derepressed the transcriptional suppression of
rDNA by methylated UBF in response to SETDB1. Furthermore, methyl-
ation site mutant UBF (K232/254A) restored the transcriptional level of
intermediate (5′-ETS) and mature (18S and 28S) rRNA levels while
SETDB1 decreased the expression of rRNA through the methylation
of wild type UBF. We also determined that 45S levels were down
regulated by SETDB1. Our data suggests that the increased level of
methylated UBF is correlated with deregulation of ribosomal trans-
cription in HD, and the SETDB1-dependent trimethylation of UBF
plays a direct role in the regulation of nucleolar chromatin plasticity
(Fig. 2). Targeting of UBF trimethylation to regions of heterochromatin
is sufﬁcient to induce large-scale chromatin condensation in the nucle-
olus. In this paradigm, the binding of trimethylated UBF throughout the
rDNA gene repeat might contribute to the formation of the inactive
chromatin state of rDNA genes. It remains to be determined, however,
how mthtt and HD-related cellular changes modulate the association
of ESET to the UBF complex. It will also be important to precisely deﬁne
the demethylationmechanismof UBF in order tomore fully understand
the dynamic role of UBF on nucleolar chromatin remodeling and rDNA
transcription in HD.
3. Therapeutic approaches for improving the nucleolar function
in HD
Genetic mutations are irreversible but epigenetic modiﬁcations are
reversible processes. In this context, from a therapeutic perspective,
epigenetic modiﬁcations are regarded as a useful therapeutic target.
Small compounds that dynamically inhibit HDAC activity can modulate
the status of rDNA transcription by post-translational modiﬁcations
of histone and non-histone molecules, as well as remodeling of the
chromatin structure in HD. Therefore, the development of such drug
agents that realign the epigenetic balance and subsequently improve
HD-related deﬁcits in the nucleolus is necessary in HD-related
researches. Because the acetylation on lysine residue in the UBF trans-
forms nucleolar chromatin structure locally and results in increased
DNA transcription, HDAC inhibitors can promote acetylation of UBF
and transcription of rDNA. Indeed, trichostatin A, a deacetylase inhibi-
tor, enhances UBF acetylation and rDNA gene expression [39,26].
We also found that sodium butyrate elevates rDNA transcription inmu-
tant HD Q111 cells and WT Q7 cells in the presence of UBF1 in a dose-
dependent manner [40]. Our group has shown that the increased
acetylation of transcription factors by three structurally distinct HDAC
inhibitors improves neuronal survival in response to oxidative stress
[66]. Collectively, these studies are consistent with a model in which
altered rDNA transcription is an additional mechanism contributing to
the protective effects of HDAC inhibitors in neurons. HDAC inhibitors
have been preclinically tested in many neurodegenerative conditions,
including animal models of HD, amyotrophic lateral sclerosis (ALS),and multiple sclerosis [49,54–56,67,68]. Taken together, it is encourag-
ing that HDAC inhibitors may improve phenotypes by upregulating
rDNA transcription that is repressed in HD [40,49,54–56]. However,
the underlying mechanisms whereby HDAC inhibitors modulate the
function of nucleolus remain to be investigated. Thus, further studies
will be needed to clarify the contribution of UBF1 acetylation and
rDNA transcription to the neuroprotective effects of HDAC inhibitors.
4. Conclusions
Alterations of epigenetic modiﬁcation in the nucleolus are closely as-
sociated with HD pathogenesis. In this context, posttranslational modiﬁ-
cations of UBF play an important role in the regulation of nucleolar
chromatin structure and transcription in striatal cells. Interestingly, an
imbalance of transcriptional homeostasis through UBF hypoacethylation
and hypermethylation provides another layer of pathological mecha-
nisms that are relevant to HD.
While the increased acetylation of UBF by CBP up regulates the tran-
scription of rDNA under normal condition, the decreased acetylation of
UBF due to the deﬁciency of CBP HAT activity leads to the down regula-
tion of rDNA transcription in HD. Since HDAC inhibitor increases the
acetylation of UBF, the use of small compounds targeting HDAC in
particular may be a successful therapeutic strategy for ameliorating
the rDNA transcription in HD [40]. However, approaches using HDAC
inhibitor-based therapeutic interventions need improved target speci-
ﬁcity for UBF-dependent nucleolar transcription in HD. Otherwise, the
trimethylation of UBF by HMT elevates the occupancy of UBF to the
promoter region of rDNA, which condensates the structure of nucleolar
chromatin, and leads to the down regulation of rDNA transcription.
Prevention of UBP hypermethylation by inhibiting HMT activity may
also be useful therapeutic targets for treating HD. It is evident that the
status of UBF acetylation and methylation is an important marker
directly or indirectly associated with transcriptional abnormality in
the nucleolus of HD [40]. However, it remains to be further investigated
whether epigenetic alterations are a fundamental aspect of HD patho-
genesis or not. Accordingly, future studies are required to address
whether epigenetic alterations in the nuclelous play a key role as a
maker of disease progress in HD.
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